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S288 Poster Session IIT cell depletion (TCD) has successfully reduced the risk of graft ver-
sus host disease (GVHD) but concerns about relapse and infections
have limited its application.
Methods: Between 7/2001 and 12/2005, 35 pts underwent TCD
HSCTs as treatment for hematologic malignancies using HLA-
matched (HLA-M)(20 pairs) or mismatched (-MM)(15 pairs) unre-
lated donors. The conditioning regimen, hyperfractionated total
body irradiation (1375 cGy), fludarabine (25 mg/m2) x 5d, and thio-
tepa (5 mg/kg) and antithymocyte globulin 2d, was designed to re-
duce toxicity, while preserving immunosuppression for engraftment.
Donors were $8 of 10 HLA matched by DNA SSOP analyses. Pts
received TCD-peripheral blood stem cells (PBSC) (n5 29) or
TCD-bonemarrow (BM) (n5 6). PBSCs were CD34+ selected (Iso-
lex 300i columns) and BMs agglutinated by soybean lectin, after
which both underwent sheep erythrocyte-rosette sedimentation.
The median age was 40.5yrs (18-63). Diseases included AML (stan-
dard or high risk) and ALL (high risk) CR1, AMLCR2, ALL$CR2,
acute biphenotypic leukemia, CML-CP,MDS, T-PLL.Median fol-
lowup is 52 mos (37-83).
Results: All evaluable pts engrafted neutrophils, and 31/34 evalu-
able pts engrafted platelets. The 100d non-relapse mortality was
20% with infection causing .50% of deaths. 9% developed only
acute GVHD grade II-III and 29% chronic GVHD, with no signif-
icant difference between HLA-M and -MM subsets. Estimated 4 yr
DFS and OS is 56% and 59%, with DFS of 75% for pts with stan-
dard risk and 41% for high risk disease. Two high risk disease pts
relapsed at 31 and 38 mos. Infectious deaths were: 2 viral, 1 toxo-
plasma, 1 fungal, 2 bacterial. Median time to achieve normal
CD3 +CD8+ and CD3 +CD4+ counts were approximately 4-6
and 6-9 mos posttransplantation, respectively. Only 4 pts, who
had been treated with steroids, had CD3 +CD4+ counts \100
cells/ul by 1 yr. 50% of patients reached a normal PHA proliferative
response in vitro within 1 yr.
Conclusions: Outcomes with this cytoreductive regimen followed
by TCD PBSC or BM are similar to those reported for TCD
matched related donor, and for unmodified transplants but with
a much lower incidence of GVHD. Relapse rates, with followup of
.3 yrs, remain remarkably low.351
ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION IN PATIENTS
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The incidence of liver related morbidity and mortality after al-
logeneic hematopoietic cell transplantation (Allo-HCT) in patients
positive for hepatitis B surface antigen (HBsAg +) may increase,
but it has been not well analysed. The aim of this study is to de-
termine the frequency of HBV reactivation and to evaluate the ef-
fect of HBV reactivation on early transplant-related complications
in a retrospective single center cohort. We detected HbsAg+ 23
patients (3.8%) who underwent allo-HCT (n5 680) within 10
years. Median age was 33 years. Twenty-two were male and one
female. Liver function tests were normal and HBV-DNA negative
in 20 patients prior to the transplant. Myeloablative (n5 20) or
fludarabine based-reduced intensity conditioning regimen (n5 3)
were used. Lamivudin prophylaxis was initiated 100 mg p.o o.d.
in 14 patients with conditioning regimen and was continued until
6-12 months after the cessation of immunosuppresion at post-
transplant period. Six patients had HBsAg+ donor, 5 seropositive
(antiHBs with antiHBc IgG, 3 antiHBs alone and 6 were negative
HBV naive. We could not obtain enough data about HBV serol-
ogy of 3 donors. HBV reactivation was observed in 7 patients after
median 4.5 months (range, 0.87-23.5) after the Allo-HCT. All the
patients with HBV reactivation had received myeloablative condi-
tioning. There was an increase of serum ALT (2.5UNL- 54
UNL) level with positivity for HBV-DNA during reactivation.
The reactivation was observed only in one patient during lamivu-
dine prophylaxis 7.6% vs 60%. p5 0.012) while one patient expe-
rienced a reactivation in 2 months after cessation of prophylaxis.Two patients with HBV reactivation had donors positive for
HBsAg. Lamivudin treatment was given in 5 patients after reacti-
vation. Lamivudin resistance was observed in two patients, who re-
ceived second line antiviral treatment. One of those patients died
of fulminant hepatic failure. The incidences of acute or chronic
liver graft versus host disease were not affected from HBV reacti-
vation. The reactivation HBV is one of the most undesired com-
plications of chemo/immunosuppressive treatment in HBsAg
positive Allo-HCT recipients. The prophylaxis with lamivudine
could decrease the frequency of HBV reactivation. But the devel-
opment of the lamivudine resistance is another problem in some
patients requiring long-term treatment. In conclusion, our study
has shown that HBsAg+ recipients did not have a strict limitation
for allo-HCT.352
QUANTITATIVE ANALYSIS OF LINEAGE-SPECIFIC CHIMERISM FOR MON-
ITORING POST-HAEMATOPOIETIC STEM CELL TRANSPLANTATION EN-
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Haematopoietic stem cell transplantation (HSCT) is an estab-
lished treatment for various hematological disorders. The moni-
toring of post-transplant engraftment has become a routine
diagnostic assay in the clinical laboratory. PCR-based methodolo-
gies utilizing STR analysis and commercial multiplex assays are
frequently used. However, these commercial kits were originally
formulated for forensic applications and do not completely fulfill
the needs of diagnostic chimerism testing, especially for non-mye-
loablative bone marrow transplants, in which treatment depends
on the status of lineage-specific chimerism. We utilize the Beck-
man-Coulter GenomeLab Human STR Primer Set (Fullerton,
CA) in our clinical laboratory. This kit consists of twelve STR
markers in a single multiplex PCR reaction and has proven highly
informative, sensitive and rapid in routine clinical testing. For use
with this kit, DNA is extracted from peripheral blood, bone mar-
row, and/or CD3/CD33/CD56-enriched fractions sorted on the
BD Biosciences FACSAria Cell Sorting System (San Jose, CA)
and extracted with the Qiagen Blood Kit or Qiagen Micro Kit
(Valencia, CA). 60 blood samples from multiple College of Amer-
ican Pathologists (CAP) proficiency panels were evaluated. These
panels are challenges proctored by CAP and participated in by
up to 80 US labs 3 times per year. Correlation of results were ex-
cellent (r25 0.99). This method has been in use by our laboratory
since the summer of 2005 with approximately 4500 patient sample
studies. In our experience no pre-transplant/donor combination
has yielded a non-informative result, even between siblings. We
have found the STR-based method to be a rapid, specific, sensi-
tive, and cost-effective diagnostic assay for monitoring donor
cell engraftment after HSCT transplantation, making it a respon-
sive tool for rapid clinical decision making. The assay is stream-
lined to provide rapid turn-around-time and requires a minute
amount of DNA making it an excellent tool for patients with
low white blood cell counts. This methodology is also suitable
for detection of maternal cell contamination and for verifying pa-
thology specimen identification.353
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The St. Louis Cord Blood Bank (SLCBB) serves to collect,
process, cryopreserve, and distribute umbilical cord blood for hu-
man transplantation. To date, nearly 1,600 units have been dis-
tributed globally for the treatment of more than 70 diseases
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Anemia (SAA). Recent data, although limited, has suggested
that unrelated cord blood transplantation can be a successful
treatment strategy for patients with SAA lacking a well-matched
adult donor. A retrospective analysis was performed as a means
to compare the SLCBB experience (n5 42) with published re-
sults. Outcomes data was available and evaluated for 16 singleton
cord transplants. This population included 11 pediatric and 5
adult patients. The mean age was 15.4 years (1.7-45.2). Donor/
recipient HLA matching was six of six (n5 2), five of six
(n5 8), four of six (n5 6). Median total nucleated cell dose
was 7.2  107/kg. Fourteen patients received myeloablative con-
ditioning regimens while two received non-myeloablative condi-
tioning. Thirteen patients achieved neutrophil engraftment with
a median time to recovery of 21 days (9-46). The six patients
who received a total nucleated cell dose (TNC) . 5.0  107/
kg had a median time to engraftment of 20 days as compared
to 27 days for patients receiving a TNC dose\5.0  107/kg.
There was one instance of graft failure and one patient censored
due to early death. Ten patients are alive and three have expired
from infectious complications. Acute GVHD occurred in nine
patients and chronic GVHD developed in six. Outcomes for
dual cord transplants (n5 11) were available for three patients.
All three patients engrafted with a median time to absolute neu-
trophil recovery of 25 days (22-28). These findings support that
unrelated cord blood transplant is a feasible treatment strategy
for Severe Aplastic Anemia. The SLCBB will continue to track
and report outcomes for this population.354
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFI-
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Introduction: Primary and post-ET/PV-myelofibrosis (MF) is
a rare myeloproliferative disorder with a very variable, on the long
term always fatal course. After allogeneic hematopoietic cell trans-
plantation (alloHCT) encouraging short term survival has been re-
ported. We present data from 57 consecutive transplants for MF in
our institution, demonstrating that close monitoring of the post-
transplant course is warranted.
Methods: Between 2000 and 2009 40 males and 17 females with pri-
mary MF (n5 48) and MF post ET or PV (n5 9) were grafted with
unmanipulated bone marrow (n5 22) or peripheral stem cells
(n5 35) from a related (n5 14) or an unrelated (n5 43) donor. Me-
dian (md) age was 54 (19-68) years. Fifteen patients (pts) had low, 28
intermediate and 14 high risk disease (Dupriez score 0, 1, 2). Karyo-
type was favorable in 35, unfavorable in 16 and unsuccessful in 6 pts.
All but four pts received intermediate intensity conditioning
(TBI(8 Gy)/Flud/Cy n5 29 or Bu(10)/Flud n5 24, standard
n5 4). In all except 4matched transplants rabbit ATGwas added be-
fore grafting.
Results: All pts engrafted at a md of 25 (11-70) days. 16 pts either
transiently or permanently lost complete chimerism during follow
up with proven relapse at a md of 376 (69 – 1211) days in 12. Overall
probability of relapse at 4 years is 32%. At a md follow up of 46 (4-
115) months probability of overall versus relapse free survival (RFS)
is 66% vs 50% for the whole cohort. Probability of RFS is signifi-
cantly less in pts with unfavorable karyotype compared to those
with favorable karyotype (21 vs 63%, p5 0.004) and for pts with cir-
culating blasts. 1% compared to those with blasts\5 1% (27 vs
61%, p5 0.002). Twelve pts with decreasing chimerism/relapse re-
ceived immunotherapy (6 PBSC boosts, 8 donor lymphocyte infu-
sions) with 8 patients responding. In 6 pts response was complete,
2 subsequently lost their response and 5 ultimately had to receive
a second transplant
Conclusions: Our results underscore the need for closely moni-
toring MF pts after alloHCT. Problems with loss of donor chi-
merism and relapse post-transplant are common however maywell respond to cellular immunotherapy. For full evaluation of
the role of alloHCT in the management of MF long term results
are warranted.355
ADDITION OF BUSULFAN TO FLUDARABINE AND TOTAL BODY IRRADIA-
TION CONDITIONED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION ENHANCES DONOR T-CELL ENGRAFTMENT AND
OPTIMIZES DISEASE CONTROL
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Lattin, B., Gajewski, J., Kovacsovics, T., Slater, S., Jacoby, C.,
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While nonmyeloablative allogeneic hematopoietic stem cell trans-
plantation (HSCT) is associated with a reduction in treatment asso-
ciated toxicity, limitations in disease control continue to impact
overall outcomes. Key to optimizing disease remission is the rapid
integration of the donor T cell compartment to maximize graft vs.
malignancy activity. While details on the kinetics of engraftment
in nonmyeloablative HSCT is limited, reports by two groups (Baron
F. et al, Blood, 2004,104:2254 and Saito B. et al, BBMT, 2008
14:1148) concur that low donor T-cell chimerisms by Day +30 por-
tend poorer outcomes from either disease progression or engraft-
ment failure. Therefore, manipulation of the transplant procedure
to optimize engraftment outcomes early in the post-transplant
course is vital to maximize outcomes. To this end, we established
an institutional reduced-intensity regimen of busulfan 3.2 mg/kg
IV, fludarabine 90 mg/m2 and TBI 2 Gy followed by allogeneic pe-
ripheral blood stem cell transplant. Our GVHD prophylaxis regi-
men includes cyclosporine and MMF. This report describes our
early T cell chimerism data in 76 patients and shows a correlation be-
tween T cell chimerism and disease control.
The mean percentage of donor CD3+ cells was 72% at Day +28,
98% at Day +56 and 99.9% at Day +84, which compare favorably
to previous reports of engraftment with fludarabine and TBI alone.
We further analyzed chimerism data in those patients with measur-
able disease going into transplant and those with early relapse despite
remission at the time of transplant. In 13 patients that were not in
complete remission at the time of transplant, but subsequently
achieved complete remission, the mean CD3+ donor cells at Day
+28 was 85% and 92% at Day +56. This is in stark contrast to the
group of 7 patients who were in complete remission at the time of
transplant, but rapidly relapsed post-transplant, with a mean Day
+28 CD3+ donor cells of 57%, with minimal improvement to an av-
erage of 63% at Day +56, statistically significantly different from the
group achieving remission. Additional findings with this regimen in-
clude 2 year survival of 49%, with acceptable levels of GVHD.
The addition of busulfan to the backbone of fludarabine and TBI
enhances early T cell engraftment, leading to optimal disease control
by harnessing graft vs. malignancy activity. Early poor T cell chime-
risms may define those at high-risk of relapse, prompting interven-
tions to enrich donor T cell constitution.356
TARGETED IV BUSULFAN AND FLUDARABINE FOLLOWED BY POST-AL-
LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RITUXIMAB DEM-
ONSTRATE ENCOURAGING ACTIVITY IN HIGH RISK CD20 + POSITIVE
LYMPHOID MALIGNANCIES WITHOUT INCREASED INFECTIOUS COMPLI-
CATIONS
Roman-Diaz, J.L., Pidala, J., Nishihori, T., Perkins, J., Tate, C.,
Ochoa, J., Ayala, E., Fernandez, H.F., Anasetti, C., Kharfan-
Dabaja, M.A. Moffitt Cancer Center, Tampa, FL
Rituximab has activity in lymphoid malignancies and may aug-
ment responses after allogeneic hematopoietic cell transplantation
(HCT); however prolonged lymphopenia may increase the risk
for infectious complications. We examined the safety of Rituximab
after reduced toxicity conditioning HCT. Sixteen patients (median
age 56, range 35 – 68), (CLL 7, follicular lymphoma 4, mantle cell
lymphoma3, and large cell lymphoma 2 with CD20 positive lym-
phoid malignancies. Twelve had a partial response and 4 complete
